There was no additive effect on tumor ablation when IFNγ/TRAIL-ADSCs were co-injected with the melanoma cells, indicating that presence of IFNγ is solely responsible for tumor reduction (Figure 6, A and D, left panel). The gene discussed is IFNG; the disease is melanoma.